相似文献
1
Malondialdehyde in benign prostate hypertrophy: a useful marker?
Mediators Inflamm. 2003 Apr;12(2):127-8. doi: 10.1080/0962935031000097745.
2
Oxidative stress in benign prostate hyperplasia.
Nepal Med Coll J. 2007 Dec;9(4):222-4.
3
Oxidative stress in patients with benign prostate hyperplasia.
JNMA J Nepal Med Assoc. 2007 Jul-Sep;46(167):103-6.
4
Association of Pb, Cd, and Se concentrations and oxidative damage-related markers in different grades of prostate carcinoma.
Biol Trace Elem Res. 2012 Jan;145(1):23-32. doi: 10.1007/s12011-011-9162-2. Epub 2011 Aug 2.
5
A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Prostate Cancer Prostatic Dis. 2007;10(4):356-9. doi: 10.1038/sj.pcan.4500965. Epub 2007 Apr 3.
6
Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Urology. 2005 Feb;65(2):300-5. doi: 10.1016/j.urology.2004.09.030.
7
Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
BJU Int. 2006 Apr;97(4):742-6. doi: 10.1111/j.1464-410X.2006.06016.x.
8
Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Iran J Immunol. 2009 Jun;6(2):92-8.
9
IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Eur Urol. 2006 Feb;49(2):286-92; discussion 292. doi: 10.1016/j.eururo.2005.08.022. Epub 2005 Dec 7.
10
The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Int J Impot Res. 2008 Dec;20 Suppl 3:S19-26. doi: 10.1038/ijir.2008.53.
引用本文的文献
1
Oxidative Stress and Skin Diseases: The Role of Lipid Peroxidation.
Antioxidants (Basel). 2025 May 7;14(5):555. doi: 10.3390/antiox14050555.
2
Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.
Diseases. 2025 Feb 11;13(2):53. doi: 10.3390/diseases13020053.
3
Malondialdehyde as a Potential Oxidative Stress Marker for Allergy-Oriented Diseases: An Update.
Molecules. 2023 Aug 9;28(16):5979. doi: 10.3390/molecules28165979.
4
Alleviates Progression of Benign Prostatic Hyperplasia in vitro and in vivo.
Res Rep Urol. 2022 Sep 24;14:313-326. doi: 10.2147/RRU.S381713. eCollection 2022.
5
Oxidative Stress Biomarkers in Age-Related Lower Urinary Tract Disorders: A Systematic Review.
Int Neurourol J. 2022 Mar;26(1):3-19. doi: 10.5213/inj.2142188.094. Epub 2022 Mar 31.
6
Inhibitory effects of seed oil on the testosterone-induced benign prostatic hyperplasia in rats.
Biomedicine (Taipei). 2021 Mar 1;11(1):19-25. doi: 10.37796/2211-8039.1083. eCollection 2021.
7
Oxidative Stress Links Aging-Associated Cardiovascular Diseases and Prostatic Diseases.
Oxid Med Cell Longev. 2021 Jul 17;2021:5896136. doi: 10.1155/2021/5896136. eCollection 2021.
8
Serum paraoxonase 1 and 3 activities in benign and malignant diseases of the prostate and changes in levels following robotic-assisted laparoscopic radical prostatectomy.
Turk J Med Sci. 2020 Dec 17;50(8):1872-1878. doi: 10.3906/sag-2004-353.
9
Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer.
Sci Rep. 2020 Jun 4;10(1):9093. doi: 10.1038/s41598-020-65918-w.
10
Mangosteen pericarp components alleviate progression of prostatic hyperplasia and mitochondrial dysfunction in rats.
Sci Rep. 2020 Jan 15;10(1):322. doi: 10.1038/s41598-019-56970-2.
本文引用的文献
1
The role of apoptosis in aging and age-related disease: update.
Z Gerontol Geriatr. 2001 Dec;34(6):441-6. doi: 10.1007/s003910170015.
2
Indices of lipid peroxidation in vivo: strengths and limitations.
Free Radic Biol Med. 2000 Jun 15;28(12):1745-50. doi: 10.1016/s0891-5849(00)00232-x.
3
Diseases of aging.
Vaccine. 2000 Feb 25;18(16):1567-83. doi: 10.1016/s0264-410x(99)00489-2.
4
[Prostate-specific antigen in prostatic pathology].
Ann Urol (Paris). 1988;22(3):193-6.
Zotero 插件